We hypothesized that everolimus would enhance irinotecan therapy due to the modulation of effectors on pro-survival pathways and aimed to evaluate the combination in mouse xenograft models of CRC harboring the difficult to treat concurrent PIK3CA and KRAS or BRAF mutations. This evidence concerns the gene KRAS and colorectal carcinoma.